pexmetinib

Pexmetinib is an orally bioavailable small molecule that acts as a dual inhibitor of the p38 mitogen-activated protein kinase (MAPK) and Tie2 (TEK receptor tyrosine kinase). By inhibiting these kinases, pexmetinib may reduce the production of pro-inflammatory cytokines, decrease tumor angiogenesis, and suppress tumor cell growth and survival. The drug has demonstrated potential antineoplastic, anti-inflammatory, and antiangiogenic activities in preclinical studies. Pexmetinib was originally developed by Array BioPharma and later pursued by Pfizer for clinical development. It has been investigated primarily for hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors including malignant melanoma and renal cell carcinoma[1][2][4][5][6].

Other names

pexmetinib hydrochloride